|
|
Bioinformatics analysis of TMPRSS2, a key protease used by SARS-CoV-2 to invade host cells |
ZHANG Li-na1,2, WEN Chao-chao3, DU Xiang-xin1,2, ZHANG Yu-tong1,2, ZHAO Xin1,2, ZHANG Ce1,2, ZHANG Yu1,2 |
1. Key Laboratory of Cell Physiology, Ministry of Education (Shanxi Medical University), Taiyuan 030001,China; 2. Department of Physiology, Shanxi Medical University, Taiyuan 030001,China; 3. Department of Biochemistry and Molecular Biology, Shanxi Medical University, Taiyuan 030001,China; |
|
|
Abstract Through bioinformatics, we systematically predicted and analyzed the structure and function of TMPRSS2, a key protease used by SARS-CoV-2 to invade host cells, thus providing a reliable reference for the research on the protein and the development of its inhibitors. We used ProtParam, Protscale, SignalP 4.0 Server, SecretomeP 2.0 server, TMHMM Server v. 2.0, SOPMA, SWISS-MODEL, MEGA-X and other software to predict the structure, function, evolution, biological processes and other aspects of the TMPRSS2 gene and protein. We comprehensively analyzed and demonstrated the results obtained with each program. TMPRSS2 protein was found to be a hydrophilic protein composed of 492 amino acids. It has a transmembrane helix structure and is a non-classical secreted protein. The expression of TMPRSS2 protein in the prostate was particularly abundant, and it has abundant post-translational modification sites. TMPRSS2 protein has a total of three superfamily conserved domains, and the amino acid sequence after the 100th position is relatively conserved. We report comprehensive prediction and analysis of the structure and function of the TMPRSS2 protein. From the perspective of bioinformatics, our results verify its characteristics as a serine protease and provide a possible mechanistic explanation for its participation in SARS-CoV-2 invasion of hosts. This work should facilitate further experiments and research related to TMPRSS2.
|
Received: 13 January 2021
|
|
Fund:Supported by the Funding for The Construction of Key Disciplines of Shanxi Province’s ‘1331 Project’ (No. XK201708) and the Natural Science Foundation of Shanxi Province (No. 201801D121318) |
Corresponding Authors:
Zhang Yu,Email:zhyucnm@163.com
|
|
|
|
[1] Hoffmann M, Kleine-Weber H, Schroeder S, et al.SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J]. Cell, 2020, 181(2):271-280. DOI: 10.1016/j.cell.2020.02.052 [2] Djomkam ALZ, Olwal CO, Sala TB, et al.Commentary: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J]. Frontiers Oncol, 2020, 10:1448. DOI: 10.3389/fonc.2020.01448 [3] Glowacka I, Bertram S, Muller MA, et al.Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response[J]. J Virol, 2011, 85(9):4122-4134. DOI: 10.1128/JVI.02232-10 [4] Heurich A, Hofmann-Winkler H, Gierer S, et al.TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein[J].J Virol,2014,88(2): 1293-1307. DOI: 10.1128/JVI.02202-13 [5] Paoloni-Giacobino A, Chen H, Peitsch MC, et al.Cloning of the TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, and SRCR domains and maps to 21q22.3[J]. Genomics, 1997, 44(3):309-320. DOI: 10.1006/geno.1997.4845 [6] 郭晓强, 桂耀庭, 蔡志明. 前列腺癌中TMPRSS2-ETS基因融合及机制研究进展[J]. 遗传, 2011, 33(2):117-122. DOI: 10.3724/SP.J.1005.2011.00117 [7] Shen LW, Mao HJ, Wu YL, et al.TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections[J]. Biochimie, 2017, 142:1-10. DOI: 10.1016/j.biochi.2017.07.016 [8] Lukassen S, Chua RL, Trefzer T, et al.SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells[J]. EMBO J, 2020:e105114. DOI: 10.15252/embj.20105114 [9] Walls AC, Park YJ, Tortorici MA,et al.Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein[J]. Cell, 2020, 181(2):281-292. DOI: 10.1016/j.cell.2020.02.058 [10] Ju B, Zhang Q, Ge J, et al.Human neutralizing antibodies elicited by SARS-CoV-2 infection[J]. Nature, 2020, 584(7819):115-119. DOI: 10.1038/s41586-020-2380-z [11] Matsuyama S, Nao N, Shirato K, et al.Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells[J]. P Nat Acad Sci, 2020, 117(13):7001-7003. DOI: 10.1073/pnas.2002589117 [12] Iwata-Yoshikawa N, Okamura T, Shimizu Y, et al.TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection.[J]. J Virol, 2019,93(6). DOI:10.1128/JVI.01815-18 [13] Kawase M, Shirato K, van der Hoek L, et al. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry[J]. J Virol, 2012, 86(12):6537-6545. DOI: 10.1128/JVI.00094-12 [14] Sacconi A, Donzelli S, Pulito C, et al.TMPRSS2, a SARS-CoV-2 internalization protease is downregulated in head and neck cancer patients[J]. J Experiment Clin Cancer Res, 2020, 39(1):200. DOI: 10.1186/s13046-020-01708-6 [15] Ragia G, Manolopoulos VG.Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies[J]. European J Clin Pharmacol,2020,76(12):1623-1630. DOI: 10.1007/s00228-020-02963-4 [16] Lucas JM, Heinlein C, Kim T,et al.The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis[J]. Cancer Discov, 2014, 4(11):1310-1325. DOI: 10.1158/2159-8290.CD-13-1010 [17] Stopsack KH, Mucci LA, Antonarakis ES,et al.TMPRSS2 and COVID-19: serendipity or opportunity for intervention[J]. Cancer Discov, 2020, 10(6):779-782. DOI: 10.1158/2159-8290. [18] Lechien JR, Radulesco T, Calvo-Henriquez C,et al.ACE2 & TMPRSS2 expressions in head & neck tissues: a systematic review[J]. Head Neck Pathol, 2020, 20:1-11. DOI: 10.1007/s12105-020-01212-5 [19] Bilinska K, Jakubowska P, Von Bartheld CS,et al.Expression of the SARS-CoV-2 Entry Proteins, ACE2 and TMPRSS2, in cells of the olfactory epithelium: identification of cell types and trends with age[J]. ACS Chem Neurosci,2020, 3(11):1555-1562. DOI: 10.1021/acschemneuro.0c00210 [20] Baughn LB, Sharma N, Elhaik E, et al.Targeting TMPRSS2 in SARS-CoV-2 infection[J]. Mayo Clin Proc,2020, 95(9):1989-1999. DOI: 10.1016/j.mayocp.2020.06.018 [21] Choudhary S, Silakari O.Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19[J]. Virus Res, 2020, 289:198146. DOI: 10.1016/j.virusres.2020.198146 [22] Baron J, Tarnow C, Mayoli-Nussle D, et al.Matriptase, HAT, and TMPRSS2 activate the hemagglutinin of H9N2 influenza A viruses.[J]. J Virol, 2013, 87(3):1811-1820. DOI: 10.1128/JVI.02320-12 [23] Harbig A, Mernberger M, Bittel L, et al.Transcriptome profiling and protease inhibition experiments identify proteases that activate H3N2 influenza A and influenza B viruses in murine airway[J]. J Biolog Chemis, 2020, 295(33): 11388-11407. DOI: 10.1074/jbc.RA120.012635 [24] Dong M, Zhang J, Ma X, et al, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19[J]. Biomed Pharmacother, 2020, 131:110678. DOI: 10.1016/j.biopha.2020.110678 [25] Kim TS, Heinlein C, Hackman RC,et al.Phenotypic analysis of mice lacking the Tmprss2-encoded protease[J]. Mol Cell Biol, 2006, 26(3):965-975. DOI: 10.1128/MCB.26.3.965-975 |
|
|
|